EN IT

Reserved

Kyverna Therapeutics cede l'1,5%: i venditori tornano protagonisti dopo la pausa

·46 min read
EXECUTIVE VIEW

Il segnale di vendita su Kyverna Therapeutics (KYTX) e' alla nona settimana: i venditori tornano protagonisti dopo una breve pausa, con il 72% dei volumi in vendita e il flusso di denaro ancora negativo. Analisi tecnica completa e livelli operativi.

Reserved analysis Subscribe to read →
Reserved

Kyverna Therapeutics slips 1.5% as sellers retake control after the pause

·46 min read
EXECUTIVE VIEW

The sell signal on Kyverna Therapeutics (KYTX) reaches its ninth week: sellers regain control after a brief pause, with 72% of volume on the sell side and money flow still negative. Full technical analysis and trading levels inside.

Reserved analysis Subscribe to read →
Reserved

Kyverna Therapeutics quasi piatta (-0,5%): il doppio minimo tiene e i compratori tornano

·46 min read
EXECUTIVE VIEW

Analisi tecnica settimanale sulle azioni Kyverna Therapeutics: dopo il tonfo del 12,2% della scorsa settimana, quella appena chiusa e' quasi piatta, coi compratori tornati al 63% dei volumi e un doppio minimo che tiene nell'area 7,1-7,2.

Reserved analysis Subscribe to read →
Reserved

Kyverna Therapeutics nearly flat (-0.5%): double bottom holds as buyers return

·46 min read
EXECUTIVE VIEW

Kyverna Therapeutics weekly technical analysis: after last week's 12.2% plunge, the week just closed is nearly flat, with buyers back to 63% of volume and a double bottom holding firm in the 7.1-7.2 area.

Reserved analysis Subscribe to read →
Reserved

Kyverna Therapeutics cede il 12,2%: lo short torna quasi in pareggio dopo sei settimane

·46 min read
EXECUTIVE VIEW

Analisi tecnica settimanale sulle azioni Kyverna Therapeutics: il titolo cede il 12,2%, i venditori tornano al comando dopo il rimbalzo della settimana scorsa, e lo short di gestione risale quasi al pareggio grazie al nuovo affondo del prezzo.

Reserved analysis Subscribe to read →
Reserved

Kyverna Therapeutics drops 12.2%: the short is back near breakeven after six weeks

·46 min read
EXECUTIVE VIEW

Kyverna Therapeutics weekly technical analysis: the stock drops 12.2% as sellers retake control after last week's bounce, and the swing short under management climbs back near breakeven thanks to the fresh leg lower.

Reserved analysis Subscribe to read →
Share WhatsApp Telegram Gmail LinkedIn